Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative...
-
Upload
asher-carson -
Category
Documents
-
view
214 -
download
2
Transcript of Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative...
![Page 1: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/1.jpg)
Migraine Prophylaxis in Patients with
Patent Foramen Ovale:
PFO Closure vs. Traditional Preventative
Measures
By: Samantha HowellSubmitted to: Dr. Gurwell
![Page 2: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/2.jpg)
Migraines
• 28 million Americans each year• Characterized by: pulsing or throbbing pain,
unilateral pain commonly, interferes with daily activities, worsened by physical activity
• Has to be accompanied by one of the following: N/V, photophobia, or phonophobia
• 2 types: Migraine with aura (20%)
Migraine without aura (80%)• Aura-a sensory disturbance (visual typical)
![Page 3: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/3.jpg)
Pathophysiology
• Poorly understood
• Excitation wave theory
• Cerebral ischemia
• Lungs may play a role-if bypassed allow microemboli and substances like serotonin and ADP to get to the brain via circulation
-one possibility is PFO or ASD
Neurovascular cause
![Page 4: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/4.jpg)
Patent Foramen Ovale
• Failure of foramen ovale to close at birth
• Right-to-left shunt of blood
• PFO may be present in 40-60% of migraine with aura sufferers
• Closing this defect may be a future treatment for migraine
![Page 5: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/5.jpg)
Traditional Migraine Prophylaxis
• Avoidance of Triggers
• Stress Management
• Pharmacological Prophylactic Treatments used if MHA occurs more than 2x a month, not controlled with acute tx, or the patient takes abortive tx more than 2x a week
•Anti-epileptics (Topiramate, Gabapentin)
•NSAIDS (Ibuprofen)
•Antidepressants
•Beta blockers (Atenolol)
•Calcium channel blockers (Verapamil)
•ACEi (Lisinopril)
•Magnesium
•Botox
•Other Vitamins/Minerals
![Page 6: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/6.jpg)
Clinical Question
• In patients with migraine with aura who have a known patent foramen ovale (PFO), is there a quality-of-life benefit to PFO closure surgery or would migraine symptoms be equally controlled with pharmacological prophylactic treatment?
• Methods: Three PubMed Database searches were performed to attempt to answer this question
![Page 7: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/7.jpg)
Wilmshurst, 2000
• Retrospective study looking at effects of PFO closure on migraine headaches (n=21)
• Surgery was performed to treat decompression illness
• Treated with aspirin for 6 mos. post-op• Patients were interviewed about migraine after
the surgery (had to recall symptoms before and after procedure)-IHS guidelines used to determine if patients had migraines
• 9-32 month follow-up
![Page 8: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/8.jpg)
Giardini, 2006
• Prospective study looking at long-term efficacy of PFO closure on migraine in stroke patients (n=13)
• Surgery was performed due to previous stroke• Treated with aspirin for 12 months following the
surgery• Patients were interviewed about migraine and
the condition severity was assessed using MIDAS questionnaire
• 4.9 ± 1.4 years follow-up
![Page 9: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/9.jpg)
Results
Table 1-Effect of PFO closure on migraine headaches
Study Headache Type
Cured Improved Cured or Improved
No Change or Worsened
Wilmshurst (2000)
Migraine (of any type)
10/21 (48%) 8/21 (38%) 18/21 (86%) 3/21 (14%)
Migraine with Aura
7/16 (44%) 8/16 (50%) 15/16 (94%) 1/16 (6%)
Migraine Without Aura
3/5 (60%) 0/5 (0%) 3/5 (60%) 2/5 (40%)
Giardini (2006)
Migraine (of any type)
11/13 (85%) 1/13 (8%) 12/13 (92%) 1/13 (8%)
Migraine with Aura
NA NA NA NA
Migraine Without Aura
NA NA NA NA
![Page 10: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/10.jpg)
Silberstein, 2004
• Randomized, double-blind, placebo-controlled trial (n=284)
• 26 week treatment period using 50, 100, or 200 mg/d of Topiramate and matching amounts of placebo
• Patients kept diaries recording periods with migraine headache
• Success of the drug was based on change from baseline• Percentage of patients with decreased frequency and
severity in each group: 100 mg/d Topiramate = 54% 200 mg/d Top. = 52.3% 50 mg/d Top. = 35.9% Placebo = 22.6%
![Page 11: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/11.jpg)
Schrader, 2001
• Randomized, placebo controlled, crossover study (n=60)• 30 pts. took 10 mg Lisinopril once daily for 1 wk and then
two 10 mg tablets once daily for 11 wks followed by 2 wk washout period-then one placebo pill daily for one wk and then two placebo pills once daily for 11 wks.
• Another 30 pts. took the placebo pills during the first 12 wks and lisinopril during the next 12 wks
• Patients also recorded symptoms in a diary• Results: -For days with migraine, a reduction by at least 50% was
seen in 30% of participants -32% of participants saw at least a 50% reduction in
headache severity compared to placebo period
![Page 12: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/12.jpg)
For ComparisonTable 2-Reduction of migraine activity by PFO closure vs.
Traditional Migraine Prophylaxis
Source Prophylactic Daily Dosage % Reduction in Migraine Activity
Buchanan 2006 Gabapentin (anti-epileptic) 1.8-2.4 g 36%
Botox 25 International Units 45%
Vitamin B2-Riboflavin 400 mg 56%
Coenzyme 10 300 mg microparticles 48%
Silberstein 2004 Topiramate (anti-epileptic) 100 mg/d 54%
Silberstein 2002 Propanolol (beta-blocker) 120-240 mg 44%
Magnesium 600 mg 41.6%
Aspirin (NSAID) 650 mg 20-30%
Schrader 2001 Lisinopril (ACE Inhibitor) 20 mg 30%
Wilmshurst 2000 PFO Closure N/A 86%
Giardini 2006 PFO Closure N/A 92%
![Page 13: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/13.jpg)
Study Strengths and Limitations
Strengths (PFO)• MIDAS • IHS • Follow-up 5 yrs
Strengths (Meds)
• Randomized, placebo-controlled
• Large number of subjects• Quantitative measures
Limitations (PFO)
•Sample size
•Retrospective (Wilmshurst, 2000)
•Participant Recall error
Limitations (All)
•All data gathered was somewhat subjective (participant diaries, etc.)
![Page 14: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/14.jpg)
Conclusions
• PFO closure looks promising-higher percentage of patients in the PFO closure trials had reduced frequency and severity of migraines
• PFO closure is invasive and there is not enough research
• Additionally, not everyone who has migraines has the heart wall defect
• The surgical procedure should only be recommended at this time for individuals with multiple conditions related to PFO
• Our patients with PFO and migraines should simply be placed on traditional prophylactic meds or use acute treatment until more research is done
![Page 15: Migraine Prophylaxis in Patients with Patent Foramen Ovale: PFO Closure vs. Traditional Preventative Measures By: Samantha Howell Submitted to: Dr. Gurwell.](https://reader035.fdocuments.in/reader035/viewer/2022080914/56649cef5503460f949bcddd/html5/thumbnails/15.jpg)
References• Beda RD, Gill Jr. EA. Patent foramen ovale: does it play a role in the pathophysiology of migraine headache? Cardiol Clin.
2005;23:91-96.• Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006;26:188-198.• Giardini A, Donti A, Formigari R, Salomone L, Palareti G, Guidetti D, et al. Long-term efficacy of transcatheter patent
foramen ovale closure on migraine headache with aura and recurrent stroke. Catheter Cardiovasc Interv. 2006;67:625-629.• Headache Classification Subcommittee of the International Headache Society. The international classification of headache
disorders, 2nd edition. Cephalalgia. 2004;24(Suppl. 1):1-36.• Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States. Neurology 2002;58:885.• Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: The migraine
assessment (MIDAS) questionnaire. Headache 2001;41:854-861.• Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Physician. 2006 Jan 1;73(1):72-78.• Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: a new migraine
treatment? Journal of Interv. Cardiol. 2003;16(1):39-42.• Parsekyan D. Migraine prophylaxis in adult patients. West J Med. 2000;173:341-345.• Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme
inhibitor (lisinopril): randomized, placebo controlled, crossover study. BMJ 2001;322:1-5.• Schwedt TJ, Dodick DW. Patent foramen ovale and migraine-bringing closure to the subject. Headache. 2006:46:663-671.• Schwerzmann M, Nedeltchev K, Meier B. Patent foramen ovale closure: a new therapy for migraine. Catheter Cardiovasc
Interv. 2007;69:277-284.• Silberstein S, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention. Arch Neurol. 2004;61:490-495.• Silberstein SD, Goadsby PJ. Migraine: preventative treatment. Cephalalgia 2002;22(7)491-512.• Wilmshurst P, Nightingale S, Pearson M, Morrison L, Walsh KP. Relation of atrial shunts to migraine in patients with
ischemic stroke and peripheral emboli. Am J Cardiol. 2006;98(6):831-833.• Wilmshurst PT, Nightingale S, Walsh KP, and Morrison WL. Clopidogrel reduces migraine with aura after transcatheter
closure of persistent foramen ovale and atrial septal defects. Heart. 2005;91(9): 1173-1175.• Wilmshurst PT, Pearson MJ, Nightingale S, Walsh KP, Morrison WL. Inheritance of persistent foramen ovale and atrial
septal defects and the relation to familial migraine with aura. Heart. 2004; 90(11):1315-1320.• Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to
prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet. 2000; 356(9242):1648-1651.